About bridgebio oncology therapeutics inc - BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
BBOT At a Glance
Bridgebio Oncology Therapeutics, Inc.
256 East Grand Avenue
South San Francisco, California 94080
| Phone | N/A | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | 7.60M | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BBOT Valuation
| P/E Current | 58.296 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 32.478 |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.308 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -419.492 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
BBOT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BBOT Liquidity
| Current Ratio | 10.398 |
| Quick Ratio | 10.398 |
| Cash Ratio | 9.054 |
BBOT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | 7.804 |
| Return on Equity | 8.057 |
| Return on Total Capital | 4.027 |
| Return on Invested Capital | 8.057 |
BBOT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |